RECRUITING

InvesT1D: Promoting Adolescent Investment in Diabetes Care

Talk to us

Conditions

Type 1 Diabetes

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management and clinical outcomes goals during the study. Researchers will compare changes in glucose levels, as well as adolescent and caregiver person-reported outcomes between groups.

Official Title

InvesT1D: Promoting Adolescent Investment in Diabetes Care

Quick Facts

Study Start:2024-06-25
Study Completion:2027-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06384911

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosed with type 1 diabetes ≥12 months
  2. * Utilize a continuous glucose monitor (CGM) to support diabetes management
  3. * Average daily CGM use is less than or equal to 70% of the time and/or their baseline average insulin bolus administration is less than or equal to 3 times a day
  4. * Are using diabetes technology that allows for tracking of bolus insulin administration if participant wants to work on improving daily bolus insulin administration
  5. * Cognitively able to participate in incentive program and complete surveys
  6. * Have access to a mobile phone to receive information about goal attainment and incentive updates
  7. * Have the ability to upload glucose and insulin administration data remotely per processes used by participant's diabetes care team
  8. * Caregivers are willing to participate in study and complete surveys
  1. * At time of screening, average CGM wear is greater than 70% of the time or baseline average insulin bolus administration is greater than 3 times a day
  2. * Adolescent is not interested in using diabetes technology that allows for tracking of bolus insulin administration if participant wants to work on improving daily bolus insulin administration
  3. * Cognitively or physically unable to participate
  4. * Adolescent is a ward of the state
  5. * Severe comorbidities including other major chronic health conditions that significantly impact daily management demands or health outcomes
  6. * Caregivers are not willing to participate in study and complete surveys

Contacts and Locations

Study Contact

Faisal S Malik, MD, MSHS
CONTACT
206-987-0121
faisal.malik@seattlechildrens.org

Study Locations (Sites)

Seattle Children's
Seattle, Washington, 98105
United States

Collaborators and Investigators

Sponsor: Seattle Children's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-25
Study Completion Date2027-10

Study Record Updates

Study Start Date2024-06-25
Study Completion Date2027-10

Terms related to this study

Additional Relevant MeSH Terms

  • Type 1 Diabetes